Big Pharma is still piling in: Pfizer closed its 2023 $43B Seagen deal to expand its ADC platform, and PD-1 biosimilars are expected to arrive late-decade, expanding access rather than collapsing the category, as CRA Insights noted
Both peptides require proper handling, but protocols may vary depending on your source
The recommended frequency of use depends on the specific peptide and can range from daily use to several times a week
However, severe or persistent tiredness beyond 8 weeks may indicate an individual response requiring dose adjustment or medication switch
So, Andrew, I think, you've also highlighted, you know, this market broadening, especially beyond the large cap leaders, even as AI investment continues, I think, as you touched on earlier
Food and Drug Administration how it will prevent unvetted shipments of the active pharmaceutical ingredients (API) in injectable weight loss drugs like Ozempic from entering the country